In an attempt to clarify these findings, recent meta-analyses found that elevated LC3 expression is associated with improved survival in CRC patients, whereas increased levels of Beclin-1 are associated with poor survival outcomes [31,32,33]. This evidence concerns the gene MAP1LC3A and colorectal carcinoma.